BGT-226 free base
In Stock•Starting at $76 for 1 mg
| CAS No. | 915020-55-2 |
|---|---|
| MDL No. | N/A |
| MF | C28H25F3N6O2 |
| MW | 534.50 |
| InChI Key | BMMXYEBLEBULND-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 1 mg | To Be Confirmed | $76 | In Stock | |
| 5 mg | To Be Confirmed | $181 | In Stock | |
| 10 mg | To Be Confirmed | $270 | In Stock | |
| 25 mg | To Be Confirmed | $537 | In Stock | |
| 50 mg | To Be Confirmed | $791 | In Stock |
Product Information
BGT226 free base is an imidazoquinoline compound with the structure 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline. It is substituted at position 1 with a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 with a 6-methoxypyridin-3-yl group. It functions as a dual PI3K/mTOR inhibitor and serves as an antineoplastic agent. It is classified as an imidazoquinoline, N-arylpiperazine, pyridine, organofluorine compound, and aromatic ether. It is the conjugate base of BGT226(1+).
| CAS No. | 915020-55-2 |
|---|---|
| Product Name | BGT-226 free base |
Biological Targets
PIK3R1·PIK3CB·PIK3CG·PIK3CA·PIK3R2·
Associated Conditions
Cowden disease·cancer·breast cancer
* The information provided here is compiled from public sources and is for reference only.
